BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38193476)

  • 1. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.
    Mahadevia H; Uson Junior PLS; Wang J; Borad M; Babiker H
    Expert Opin Pharmacother; 2024; 25(1):79-90. PubMed ID: 38193476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
    Lefler DS; Snook AE; Bashir B
    Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
    André T; Cohen R; Salem ME
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
    Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
    Pecci F; Cantini L; Bittoni A; Lenci E; Lupi A; Crocetti S; Giglio E; Giampieri R; Berardi R
    Curr Treat Options Oncol; 2021 Jun; 22(8):69. PubMed ID: 34110510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
    Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
    Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
    Lin KX; Istl AC; Quan D; Skaro A; Tang E; Zheng X
    Cancer Immunol Immunother; 2023 Dec; 72(12):3875-3893. PubMed ID: 37831146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment.
    Hong JH; Woo IS
    Cancer Lett; 2023 Jul; 565():216236. PubMed ID: 37209943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
    Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
    Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
    Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
    Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors.
    Salewski I; Kuntoff S; Kuemmel A; Feldtmann R; Felix SB; Henze L; Junghanss C; Maletzki C
    Cancer Immunol Immunother; 2021 Dec; 70(12):3405-3419. PubMed ID: 33870463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.
    Taïeb J; Sayah L; Heinrich K; Kunzmann V; Boileve A; Cirkel G; Lonardi S; Chibaudel B; Turpin A; Beller T; Hautefeuille V; Vivaldi C; Mazard T; Bauguion L; Niger M; Prager GW; Coutzac C; Benedikt Westphalen C; Auclin E; Pilla L
    Eur J Cancer; 2023 Jul; 188():90-97. PubMed ID: 37229836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of immune checkpoint inhibitors in colorectal cancer.
    Wang L; Huang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.
    Jin Z; Sinicrope FA
    J Clin Oncol; 2022 Aug; 40(24):2735-2750. PubMed ID: 35649217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.